Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL

References

• Kipps T J. Chronic lymphocytic leukemia. Curr Opin Hematol 2000; 7: 223–234
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson B D, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008; 111: 5446–5456
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, Eriksson I, Soderberg O, Karlsson K, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003; 101: 4952–4957
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99: 2262–2264
   PubMed Web of Science ®Google Scholar
• Isakov N, Wange R L, Burgess W H, Watts J D, Aebersold R, Samelson L E. ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity. J Exper Med 1995; 181: 375–380
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry T S, Wright G, Davis R E, Henrickson S E, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Alizadeh A A, Widhopf G, Simon R, Davis R E, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exper Med 2001; 194: 1639–1647
   PubMed Web of Science ®Google Scholar
• Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036–2041
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. New Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Orchard J A, Ibbotson R E, Davis Z, Wiestner A, Rosenwald A, Thomas P W, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111
   PubMed Web of Science ®Google Scholar
• Rassenti L Z, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. New Engl J Med 2004; 351: 893–901
   PubMed Web of Science ®Google Scholar
• Del Principe M I, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006; 108: 853–861
   PubMed Web of Science ®Google Scholar
• Deaglio S, Capobianco A, Bergui L, Durig J, Morabito F, Duhrsen U, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102: 2146–2155
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Orchard J A, Ibbotson R E, Davis Z, Thomas P W, Stevenson F K, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023–1029
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Morilla A, Osuji N, Matutes E, Morilla R, Burford A, et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 2005; 104: 2124–2132
   PubMed Web of Science ®Google Scholar
• Schroers R, Griesinger F, Trumper L, Haase D, Kulle B, Klein-Hitpass L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 750–758
   PubMed Web of Science ®Google Scholar
• Hus I, Podhorecka M, Bojarska-Junak A, Rolinski J, Schmitt M, Sieklucka M, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006; 17: 683–690
   PubMed Web of Science ®Google Scholar
• Catovsky D, Richards S, Matutes E, Oscier D, Dyer M J, Bezares R F, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239
   PubMed Web of Science ®Google Scholar
• Thornton P D, Fernandez C, Giustolisi G M, Morilla R, Atkinson S, A'Hern R P, et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 2004; 5: 145–151
   PubMedGoogle Scholar
• Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410–1416
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• van Dongen J J, Langerak A W, Bruggemann M, Evans P A, Hummel M, Lavender F L, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317
   PubMed Web of Science ®Google Scholar
• Lefranc M P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 2001; 29: 207–209
   PubMed Web of Science ®Google Scholar
• Zupo S, Isnardi L, Megna M, Massara R, Malavasi F, Dono M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996; 88: 1365–1374
   PubMed Web of Science ®Google Scholar
• Ghia P, Guida G, Scielzo C, Geuna M, Caligaris-Cappio F. CD38 modifications in chronic lymphocytic leukemia: are they relevant?. Leukemia 2004; 18: 1733–1735
   PubMed Web of Science ®Google Scholar
• Hayat A, O'Brien D, O'Rourke P, McGuckin S, Fitzgerald T, Conneally E, et al. CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47: 2371–2379
   PubMed Web of Science ®Google Scholar
• Krober A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 969–975
   PubMed Web of Science ®Google Scholar